Surfactant therapy: past, present and future

Summary Surfactant replacement in preterm infants with respiratory distress syndrome (RDS) has been a major therapeutic breakthrough and the most intensively studied intervention in neonatal medicine. Surfactant whether given prophylactically in the delivery room or in babies with established RDS re...

Full description

Saved in:
Bibliographic Details
Published in:Early human development 2013-06, Vol.89, p.S22-S24
Main Authors: Speer, Christian P, Sweet, David G, Halliday, Henry L
Format: Article
Language:English
Subjects:
Advanced Basic Science
Biological Products - therapeutic use
Delivery Rooms
Guidelines as Topic
Humans
Infant, Newborn
Infant, Premature
Neonatal and Perinatal Medicine
Neonates
Phospholipids - therapeutic use
Pneumothorax - drug therapy
Pulmonary Surfactants - therapeutic use
Randomized Controlled Trials as Topic
Respiratory distress syndrome
Respiratory Distress Syndrome, Newborn - drug therapy
Respiratory Distress Syndrome, Newborn - mortality
Surfactant
Survival Rate
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Surfactant replacement in preterm infants with respiratory distress syndrome (RDS) has been a major therapeutic breakthrough and the most intensively studied intervention in neonatal medicine. Surfactant whether given prophylactically in the delivery room or in babies with established RDS reduces the severity of RDS, the incidence of air leaks and pneumothorax and, most importantly, neonatal death. Many randomized controlled trials have explored different strategies to optimize the effect of surfactant administration and have further improved neonatal outcome. Whenever indicated, surfactant should be administered as early as possible in the course of the RDS.
ISSN:0378-3782
1872-6232
DOI:10.1016/S0378-3782(13)70008-2